- Published at
- by financialpost.com
positive
positive
News for SATELLOS BIOSCIENCE INC (ICOTD)
- Published at
- by financialpost.com
positivepositiveSatellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
– Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the s…- Published at
- by financialpost.com
positivepositiveSatellos Announces Closing of US$40M Public Offering
TORONTO — Satellos Bioscience Inc.- Published at
- by gurufocus.com
positivepositiveSatellos Announces Pricing of US$40M Overnight Marketed Public Offering
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a public biotech company developing new small molecule therapeutic ap- Published at
- by financialpost.com
mixedmixedSatellos Announces Pricing of US$40M Overnight Marketed Public Offering
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSP…- Published at
- by investing.com
positivepositiveSatellos Announces Overnight Marketed Public Offering of Common Shares By Investing.com
Satellos Announces Overnight Marketed Public Offering of Common Shares- Published at
- by gurufocus.com
positivepositiveSatellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
[url="]Satellos Bioscience Inc.[/url] (TSX: MSCL, OTCQB: MSCLF) (”Satellos” or the ”Company”), a public biotech company developing new small molecule t- Published at
- by financialpost.com
positivepositive- Published at
- by gurufocus.com
positivepositiveSatellos to Participate in Oppenheimer Movers in Rare Disease Summit
[url="]Satellos Bioscience Inc.[/url] (TSX:MSCL, OTCQB:MSCLF) (”Satellos”), a public biotech company developing new small molecule therapeutic approaches t- Published at
- by gurufocus.com
positivepositiveSatellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
[url="]Satellos Bioscience Inc.[/url] (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic- Published at
- by financialpost.com
positivepositive- Published at
- by etfdailynews.com
positivepositiveiCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below 200 Day Moving Average of $0.50
Read iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below 200 Day Moving Average of $0.50 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveiCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below Two Hundred Day Moving Average of $0.61
Read iCo Therapeutics (OTCMKTS:ICOTF) Share Price Crosses Below Two Hundred Day Moving Average of $0.61 at ETF Daily News- Published at
- by etfdailynews.com
positivepositiveiCo Therapeutics (OTCMKTS:ICOTF) Shares Down 46.9%
Read iCo Therapeutics (OTCMKTS:ICOTF) Shares Down 46.9% at ETF Daily News- Published at
- by investorideas.com
mixedmixedNew Stocks and Trading Ideas: (TSX: APLI) (TSXV: MSCL) (TSXV: RVLY) (CSE: ULTA) (CSE: AGE)
Vancouver, Kelowna, Delta, BC - May 27, 2022 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its w...- Published at
- by marketscreener.com
mixedmixedSatellos Bioscience Announces Evidence for Regeneration in Severe Model of Duchenne
Satellos Bioscience Inc. , a regenerative medicine company focused on the treatment of degenerative muscle disorders, announced today core findings from additional preclinical drug development... | September 13, 2021